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Abstract
Background: Soluble leptin receptor (OBRe), one of several leptin receptor isoforms, is the only bona fide leptin binding
protein in plasma. Our earlier studies demonstrated that OBRe modulates leptin levels in circulation. Both clinical and in vitro
studies have shown that OBRe expression is inversely correlated to body weight and leptin levels. However, it is not clear
whether OBRe plays an active role, either in collaboration with leptin or independently, in the maintenance of body weight.
Methodology/Principal Findings: To investigate the function of OBRe in the regulation of energy homeostasis, we
generated transgenic mice that express OBRe under the control of human serum amyloid P (hSAP) component gene
promoter. The transgene led to approximately doubling of OBRe in circulation in the transgenic mice than in wild type
control mice. Transgenic mice exhibited lower body weight at 4 weeks of age, and slower rate of weight gain when
compared with control mice. Furthermore, transgenic mice had lower body fat content. Indirect calorimetry revealed that
transgenic mice had reduced food intake, increased basal metabolic rate, and increased lipid oxidation, which could
account for the differences in body weight and body fat content. Transgenic mice also showed higher total circulating
leptin, with the majority of it being in the bound form, while the amount of free leptin is comparable between transgenic
and control mice.
Conclusions: These results are consistent with the role of OBRe as a leptin binding protein in regulating leptin’s
bioavailability and activity.
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Introduction
Obesity, a result of disruption in energy homeostasis, is
increasingly becoming a prevalent global pandemic. Numerous
studies have shown the importance of leptin in the regulation of
energy homeostasis [1,2,3,4,5]. By acting on the satiety center in
the hypothalamus, leptin reduces appetite and increases energy
expenditure [6]. In humans and rodents, mutations of the gene
encoding leptin lead to severe early-onset obesity, which can be
corrected by leptin treatment [4,5,7,8,9].
Leptin achieves its control on metabolic processes through its
interaction with the leptin receptor (OBR) [10], a member of the
class I cytokine family of receptors [11]. There are at least five
leptin receptor isoforms, OBRa to OBRe, which may be generated
by alternative splicing [12] or ectodomain shedding [13]. All the
leptin receptors share a common N-terminal extracellular ligand-
binding sequence, but differ considerably with variable length of
C-terminal regions. Only the full-length receptor, OBRb has been
shown to transmit leptin signal through its C-terminal tyrosine
residues and associated proteins, and is responsible for most, if not
all of the leptin’s regulatory function in energy homeostasis, as the
mutation that specifically ablates OBRb expression causes a
phenotype that is indistinguishable from that in animals without
leptin [10,12,14].
The functions and significance of the shorter isoforms of leptin
receptors are not known or fully understood. OBRa through
OBRd may mediate the degradation or additional intracellular
action of leptin by facilitating its endocytosis into cells [15],
although OBRa and OBRc were earlier proposed to transport
leptin into brain across the blood-brain barrier (BBB) given their
abundant expression in the choroid plexus of the BBB [16]. In
contrast, OBRe, also known as soluble leptin receptor (SLR) due
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shown to inhibit leptin transport into the brain [17].
OBRe is the only bona fide leptin-binding protein in circulation,
with similar leptin-binding affinity as OBRb [18]. The close
correlation of OBRe and leptin levels in energy homeostasis has
been demonstrated in several clinical studies: OBRe level is
inversely correlated with obesity and leptin levels [19,20,21];
OBRe expression is increased in response to weight loss, fasting
and food restriction [21,22]; and a higher proportion of OBRe-
bound leptin is present in circulation in the lean than the obese
individuals [21,23]. Moreover, the amount of OBRe in circulation
also seems to be influenced by leptin [19]. However, it is not clear
whether OBRe plays an active role, either in collaboration with
leptin or independently, in the maintenance of body weight.
Previous studies on OBRe were limited to cellular level [17] or
adenovirus-mediated transient over-expression in mouse [24]. To
directly evaluate the long-term effects of OBRe on metabolism and
leptin action in vivo, we generated a transgenic mouse line with
specific over-expression of OBRe in the liver.
Materials and Methods
Animal welfare
All mice used in this study were bred and housed in our animal
facility. They were maintained at 2561uC on a 12 h/12 h light/
dark cycle (7:00–19:00 h), and allowed free access to water and
rodent chow (15% kcal from fat; Harland Tekland, WI). All
experiments involving animals were reviewed and approved by
the Institutional Animal Care and Use Committee of the
University of Texas Southwestern Medical Center in Dallas
(0873-04-07-1) and Agency for Science, Technology and
Research (A*STAR) Biomedical Science Institutes in Singapore
(050129 and 080351).
Generation of OBRe over-expressing mice (hSAP-OBRe)
The hSAP-OBRe transgene, containing the mouse OBRe cDNA
under the control of the human serum amyloid P (hSAP)
promoter, was constructed by placing the 2.4 kb OBRe cDNA
and a poly-adenylation signal between rabbit b-globin introns
(Figure 1A). The backbone vector (without the mouse OBRe cDNA
insert) was a kind gift from J. Miyazaki (Osaka University), whose
laboratory developed the promoter construct and generated
transgenic mice over-expressing the p40 subunit of IL-12 [25].
The full length OBRe cDNA was amplified by PCR and cloned
into pSG-2’s EcoRI site by blunt ligation. The 4.2 kb transgene
fragment was excised from its vector by restriction digestion with
HindIII and SalI, and purified for microinjection. Transgenic
mice were identified by PCR of tail DNA using the following
primers: 59-GTG GTA AAG ACT TGA GGT GAA C-39 and 59-
GAA TTA TGA CTC TAA GGT CCA TC-39. The founder
mice were generated on a hybrid background, and were
backcrossed to the C57Bl6 background for 7 generations.
Figure 1. Structure of the OBRe transgene and its expression in hSAP-OBRe mice. (A) Full-length mouse OBRe cDNA and poly-adenylation
signal, flanked by rabbit b-globin introns, were placed downstream of the hSAP component promoter. The size of each fragment is indicated in the
diagram. Hind III and Sal I were used to linearize the transgene fragment before the microinjection procedure. (B) A representative Western blot
(OBRe) of blood plasma from a 20- to 24-week old male hSAP-OBRe transgenic mouse and its littermate control. Below the Western blot is the relative
densitometric quantification of OBRe from 4 independent pairs of hSAP-OBRe transgenic and control mouse plasma samples. (C) Quantification of
soluble leptin receptors from plasma samples of male hSAP-OBRe transgenic (N=13) and control (N=11) mice using ELISA. Data are presented as
means 6 SEM. **, P,0.01. a.u.: arbitrary units.
doi:10.1371/journal.pone.0011669.g001
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Age-matched littermates of hSAP-OBRe transgenic and control
mice were weighed weekly after weaning, and their body
composition was measured at age of 23–24 weeks by using an
EchoMRI-100 (Echo Medical Systems) essentially as previously
described [26].
Plasma collection
Blood from tail bleeding was collected in EDTA-coated
Eppendorf tubes (final concentration 5 mM), and tubes were
centrifuged at 8,000 g for 5 min at 4uC. Plasma was collected and
used for leptin and leptin receptor analysis, or stored at 280uC for
future use.
Western blotting
Five micro-litres of plasma was separated on an SDS/5%
polyacrylamide gel and transferred to PVDF membrane. The
membrane was then probed for OBRe with 0.2 mg/ml mouse
anti-leptin receptor antibody (sc-8391, Santa Cruz Biotechnology),
followed by HRP-conjugated goat anti-mouse antibody.
Quantification of plasma OBRe
OBRe concentration in plasma was measured by Mouse Leptin
R DuoSet ELISA assay (R&D Systems) with a detection limit of
15.6 pg/ml. The kit measures total leptin receptor, either bound
or free. Each concentration was determined from an average of
duplicate assays.
Gel-filtration chromatography for leptin separation
Bound and free fractions of leptin were separated by gel
filtration chromatography at 4uC. Each plasma sample (200 ml)
was incubated with 2 ml of murine recombinant
125I-leptin
(100,000 cpm, Perkin Elmer) overnight at 4uC. Of the 200 mlo f
prepared plasma mixture, only 100 ml was loaded and size-
fractionated using a Superdex 200 (GE) column on an A ¨KTA
Purifier chromatography system with 25 mM phosphate-buffered
saline (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM
KH2PO4, pH, 7.2) as the elution buffer. The amount of
radioactivity from each fraction was measured on a Perkin Elmer
Wallac Wizard 1470 Gamma Counter. In a typical elution profile,
the first peak represents the bound leptin while the last peak
represents the free leptin. The proportions of bound and free
125I-
leptin were determined by analyzing the areas under the curve of
both peaks of the chromatographic profile. Absolute concentra-
tions of bound and free leptin were calculated by multiplying the
percentage of bound and free leptin, respectively, by the total
leptin concentration and dividing by 100. Total leptin concentra-
tions were measured by ELISA assay (LINCO Research). Each
concentration was averaged from duplicate assays.
Oxymax/Comprehensive Lab Animal Monitoring System
(CLAMS)
Oxymax/CLAMS (Columbus Instruments) was used to quan-
titate individual mice on their oxygen consumption (VO2), carbon
dioxide production (VCO2), activity, and feed intake. Mice (16
week-old) were individually housed in chambers maintained at
2461uC, and given free access to chow and water. All the
measurements were taken every 15 minutes for 6 days after the
mice were acclimatized for 1 day. Basal metabolic rate (BMR) was
determined by averaging lowest plateau region of oxygen
consumption curve corresponding to resting periods. The
respiratory exchange ratio (RER) was calculated as the ratio
between VCO2 and VO2. All data collected were averaged from 6
days’ monitoring.
Statistical analysis
Data are presented as means 6 SEM. Comparisons of data
were made by using two-tailed Student’s t-test. The significant
limit was set at P,0.05.
Results
Generation of hSAP-OBRe mice
To test the effects of increased circulating OBRe on energy
homeostasis, we generated transgenic mice to achieve consistent
and sustained OBRe over-expression. Expression of the transgene
was under the hSAP promoter (Figure 1A), which has been used
previously to drive high-level expression specifically in livers of
transgenic mouse models [27,28]. To determine whether the
hSAP-OBRe transgene resulted in a higher level of OBRe in the
circulatory system, we compared OBRe levels in the plasma of the
transgenic and control mice by using Western blot analysis
(Figure 1B) and ELISA assay (Figure 1C). In both methods,
plasma OBRe level in the hSAP-OBRe mice was approximately
twice of that in the control mice. These results confirmed the
higher level of OBRe expression in the hSAP-OBRe mice.
Decreased body weight and body fat in hSAP-OBRe mice
An earlier study using adenovirus-mediated gene transfer
showed transient OBRe over-expression enhanced leptin’s effect
on body weight and food intake in ob/ob mice [24]. The
availability of hSAP-OBRe mice, with consistent and sustained
increase in OBRe level, made it possible to determine the long-
term effect of OBRe on energy homeostasis. We first measured the
body weight of male transgenic and control mice weekly for a
period of 16 weeks after weaning (Figure 2A). At 4 weeks old,
hSAP-OBRe mice weighed significantly less than their wild type
littermates, and this body weight difference persisted throughout
the monitoring period (Figure 2A). To compare the rate of weight
gain between the two genotypes, we calculated the amount of
weight difference since week 4 in hSAP-OBRe and control mice.
At week 16 and 19 (pre- and post-metabolic chamber analysis,
respectively), hSAP-OBRe mice gained significantly less weight
than the control mice, thus suggesting a slower rate of weight gain
in the transgenic mice (Figure 2B). A similar trend was also
observed in the F6 hybrid background mice that were continu-
ously fed either a high-fat diet (60% kcal fat, HFD) or a low-fat diet
(10% kcal fat, LFD) (Figure S1A–B). The growth curves under
different diets showed similar patterns in the two genotypes, with a
larger body weight gain over the first 5–7 weeks after birth,
followed by a progressively slower weight gain in subsequent
weeks.
At the end of the 16-week body weight monitoring, we analyzed
the total body fat and lean mass for both groups by MRI (magnetic
resonance imaging). hSAP-OBRe mice had significantly lower
total fat and lean mass compared with their control (Figure 2C,
2D). As the transgenic mice weighed less than the control group,
we normalized the fat and lean mass to body weight to evaluate
whether the difference was merely due to the body weight
difference. After normalization to body weight, the proportion of
body mass in fat in the hSAP-OBRe mice was still lower than their
wild type littermates (Figure 2E), while the proportion of lean body
mass was not different (Figure 2F). These data suggest that
increased OBRe may have a specific effect in reducing fat
accumulation, in addition to a general effect in preventing body
weight gain.
OBRe Reduces Obesity
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in hSAP-OBRe mice
To understand the cause of the lower body weight and body fat
in transgenic mice, we examined their daily food intake and
energy expenditure together with their littermate control mice by
using the Oxymax/CLAMS system. The tests were done over a
6-day period after 1 day of acclimatization. All mice had free
access to food and water, and were subjected to the same dark-
light cycle during the tests. Transgenic mice consumed ,11%
less food than their control littermates (Figure 3A), and showed
higher oxygen consumption during the day, and the whole-day
periods (Figure 3B and 3D). Furthermore, BMR, as measured by
basal oxygen consumption, was significantly higher in hSAP-
OBRe mice (Figure 3C). We also tested locomotor activity to
examine whether higher oxygen consumption in transgenic mice
could be accounted for by increased physical activity, however,
Figure 2. Reduced body weight and body fat mass in hSAP-OBRe transgenic mice. (A) Body weight of male hSAP-OBRe transgenic and
control mice given a standard rodent chow diet with measurements taken at three (N=4 mice per genotype) or four weeks (N=9–13 mice per
genotype) after birth. (B) Amount of weight gained by 16- or 19-week old hSAP-OBRe and control mice since the fourth postnatal week; data taken
from (A). (C, D) Absolute amounts of body fat (C) and lean mass (D) in male hSAP-OBRe transgenic and control mice at age 24 weeks (N=10 for each
genotype). (E, F) Proportion of body fat (E) and lean mass (F) in hSAP-OBRe transgenic and control mice at 24 weeks (N=10 for each genotype), which
was calculated as the percentage of their respective body weights. Data are presented as means 6 SEM. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0011669.g002
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control mice (70054613409 vs. 6956265173, N=10 in each
genotype). As the hSAP-OBRe transgenic mice had lower body
fat, we tested whether the transgenic mice showed increased use
of fat as energy source by quantifying RER. hSAP-OBRe
exhibited a significant reduction in RER especially during the
day (Figure 3E), suggesting that the transgenic mice used a higher
proportion of fat in their energy production than their control
mice.
Increased total but unchanged free leptin in hSAP-OBRe
mice
OBRe is a major leptin-binding protein in blood [18], and
higher level of OBRe in circulation may modulate free leptin
concentration by altering the distribution of free and bound leptin,
and consequently affect leptin’s action in the maintenance of
energy homeostasis. To test this hypothesis, we first measured total
plasma leptin in transgenic and control mice by ELISA, and found
that hSAP-OBRe mice had significantly higher leptin levels
(Figure 4A).
We next determined the distribution of free and bound leptin in
plasma of hSAP-OBRe transgenic and littermate control mice by
gel filtration chromatography. When
125I-leptin was incubated
with plasma and fractionated, two peaks of radioactivity were
observed (Figure 4B). Typical elution profiles of
125I-leptin-treated
plasma of hSAP-OBRe transgenic and control mice are shown in
Figure 4B. The first peak represents leptin bound to high
molecular mass protein, presumably OBRe, while the second
peak represents free monomeric leptin (Figure 4B). Transgenic
mice showed apparently higher peak level of radioactivity for
bound leptin than the control mice (Figure 4B). To estimate the
proportion of bound and free leptin from the elution profiles, we
calculated the area under the curve of each peak, and found
hSAP-OBRe mice had a higher proportion of leptin circulating in
bound form and a smaller proportion of circulating free leptin
when compared with the wild type mice (Figure 4C). When the
percentages of the leptin proportions were calculated into absolute
concentrations, a higher level of circulating leptin was present as
the bound form in the hSAP-OBRe mice, while the amount of free
leptin was similar between the transgenic and control mice
(Figure 4D).
Discussion
Here, we investigated the long-term metabolic impact of soluble
leptin receptor (OBRe) over-expression in vivo by analysing the
OBRe over-expressing hSAP-OBRe mice. Because OBRe may be
generated by either alternative splicing or ectodomain shedding of
membrane containing OBRs [13,29,30], it is not possible to study
the function of OBRe in vivo by knocking out OBRe specifically at
the protein level without affecting the other OBRs. As such, our
transgenic mice represent a valuable model to investigate the in vivo
function of OBRe and to study its interaction with leptin and other
relevant proteins in energy homeostasis, especially considering that
the level of OBRe over-expression in these transgenic mice was
just over two-fold compared with wild type levels (Figure 1B and
1C), an increase that is within physiological range. Too high an
expression level of a protein sometimes causes artefacts that mask
the real consequence of physiological increases of the protein in vivo
[31,32].
Figure 3. hSAP-OBRe mice had lower food intake and higher basal metabolic rate. (A) Daily food consumption of hSAP-OBRe transgenic
and control mice over a 6-day period for 16- to 17-week old mice. Data are presented as an average of 6 days’ measurement. (B) Circadian rhythm of
oxygen consumption in hSAP-OBRe transgenic (dashed line) and control (solid line) mice. Data shown are the representative oxygen consumption
profiles of a hSAP-OBRe transgenic and control mouse over a 24-hour monitoring period. (C) BMR (ml/hour/kg lean mass) for hSAP-OBRe transgenic
and control mice. (D) Rate of daily oxygen consumption for hSAP-OBRe transgenic and control mice during the day, night and the whole-day periods.
(E) RER of hSAP-OBRe transgenic and control mice during the day, night, and the whole-day period. All data, except in (B), are presented as means 6
SEM from the same population of male mice, with each genotype comprising 10 animals. *, P,0.05.
doi:10.1371/journal.pone.0011669.g003
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body weights (Figure 2A), and lower fat mass (Figure 2C and 2E).
These phenotypes could be due to reduced food intake (Figure 3A)
and increased metabolic rate (Figure 3B–D), both of which may be
the result of enhanced leptin action on energy regulation
[2,33,34,35]. There are at least three possible scenarios as how
OBRe functions in leptin-regulated energy homeostasis:
First, OBRe may regulate leptin availability and thus its
biological activity [36]. Leptin circulates in both free and
protein-bound form, and OBRe is a major leptin-binding protein
in circulation [11,23,37]. At 16 kDa, leptin would be more rapidly
cleared or metabolized as a monomer than when leptin is in a
much bigger protein complex, such as when bound to OBRe [19],
which may delay leptin clearance, and thus raise blood leptin
levels [24]. However, bound leptin is inactive because OBRb-
binding site on leptin is occupied by OBRe, which shares the same
leptin binding motif with OBRb [18]. Although we cannot rule out
that leptin-bound OBRe may play a role in energy homeostasis, it
is more likely that OBRe-bound leptin serves as a reservoir to
maintain a constant pool of readily available leptin [24,36].
Second, OBRe may regulate leptin transport into the
cerebrospinal fluid (CSF), and thus the amount of leptin at target
sites in the hypothalamus. Free leptin is transported into the CSF
by a high affinity but low capacity transport system in contrast to
bound leptin, whose transport is not easily saturated [38].
Therefore, there may be an increase in the total amount of leptin
in CSF in hSAP-OBRe mice. However, it is not practical to test
this hypothesis, because it is technically very difficult to extract
CSF in sufficient amount from mice for a reliable quantification of
leptin levels.
Third, OBRe may perform a regulatory role in energy
homeostasis independent of free leptin. Although the proportion
of free leptin was lower in hSAP-OBRe transgenic mice than in
control mice, it is worth noting that the absolute levels of free
leptin were similar between the two groups (Figure 4C and 4D).
When this is considered, together with the fact that the hSAP-
OBRe mice had lower body weight and body fat with reduced
food intake and increased energy expenditure, it is tempting to
suggest that OBRe may play an active role in regulating body
weight and energy homeostasis independent of free leptin. This
hypothesis may be tested in future studies that isolate the
contributions of leptin and OBRe, such as introducing the
hSAP-OBRe transgene into the leptin-deficient ob/ob mice.
In summary, our results demonstrate that OBRe is an active
component, either in collaboration with leptin as part of an
OBRe-leptin complex or independent of free leptin, in the
regulation of energy homeostasis. The finding extends the current
understanding of the functions of leptin receptor isoforms, and
Figure 4. Increased total, but unchanged free plasma leptin in hSAP-OBRe transgenic mice. (A) Concentration of total plasma leptin from
hSAP-OBRe transgenic and control mice. (B) An example of an elution profile (from FPLC) of plasma from hSAP-OBRe transgenic (dashed line) and
control (solid line) mouse. The first peak represents bound leptin, whereas the last peak represents free leptin. (C) Proportion of bound and free
plasma leptin based on the areas under the curve of both peaks of the chromatographic profile. (D) Absolute concentrations of bound and free leptin
derived from the total plasma leptin in (A) based on the proportion of each leptin form (C). All data shown, except (B), are compiled from the same
population of 20- to 24-week old male mice (N=12–13 animals per genotype), and are given as means 6 SEM. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0011669.g004
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and related disorders.
Supporting Information
Figure S1 Reduced body weight in hSAP-OBRe hybrid
background mice. (A) Body weight measurements of male hSAP-
OBRe hybrid background and control mice given HFD (N=14
per genotype) or LFD (N=12–15 per genotype) for 14 weeks.
Arrow indicates the start of the diet regime. (B) Amount of weight
gained by 18-week old hSAP-OBRe and control mice since the
third postnatal week; data taken from (A). Asterisks in red indicate
significance within the HFD groups, while those in black indicate
significance within the LFD groups. Data are presented as means
6 SEM. *, P,0.05; **, P,0.01.
Found at: doi:10.1371/journal.pone.0011669.s001 (0.47 MB EPS)
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